sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ʳ¹Ü°©¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > ʳ¹Ü°©¶¯ÎïÄ£×Ó

ǰÑÔ

ʳ¹Ü°©(esophageal carcinoma)ÊÇÓÉʳ¹ÜÁÛ×´ÉÏÆ¤»òÏÙÉÏÆ¤µÄÒì³£ÔöÉúËùÐγɵĶñÐÔ²¡±ä £¬ÆäÉú³¤Ò»Ñùƽ³£¾­ÓÉÉÏÆ¤²»µä·¶ÔöÉú¡¢Ô­Î»°©¡¢½þÈ󰩵Ƚ׶Ρ£Ê³¹ÜÁÛ×´ÉÏÆ¤²»µä·¶ÔöÉúÊÇʳ¹Ü°©µÄÖ÷Òª°©Ç°²¡±ä £¬Óɲ»µä·¶ÔöÉúµ½°©±äÒ»Ñùƽ³£ÐèÒª¼¸ÄêÉõÖÁÊ®¼¸Äê¡£ÕýÓÉÓÚÔÆÔÆ £¬Ò»Ð©Ê³¹Ü°©¿ÉÒÔÔçÆÚ·¢Ã÷²¢¿ÉÍêÈ«ÖÎÓú¡£¹ØÓÚÍÌÑʲ»³©»òÓÐÒìÎï¸ÐµÄ»¼ÕßÓ¦¾¡Ôç¾ÙÐÐθ¾µ¼ì²éÒԱ㷢Ã÷ÔçÆÚʳ¹Ü°©»ò°©Ç°²¡±ä¡£³£Óö¯ÎïÄ£×ÓΪÓÕ·¢ÐÔʳ¹Ü°©¶¯ÎïÄ£×Ó¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÑÇÏõ°·ÔÚÌåÄÚ¾­ÓÉ´úл £¬±¬·¢ÖØÌ¼ÉÕ £¬Ê¹ºËËá»òÆäËû·Ö×Ó±¬·¢ÉÕ»¯¶øÖ°© £¬²î³Ø³ÆÑÇÏõ°·¿Ú·þ»ò賦Íâ¸øÒ© £¬¾ùÄÜÓÕ·¢´óÊóʳ¹Ü°© £¬¿ÉÓÃÓÚʳ¹Ü°©µÄ×éÖ¯±¬·¢ÆøÖÆ¡¢¿¹Ê³¹Ü°©Ò©ÎïµÄɸѡºÍʳ¹Ü°©±¬·¢Àú³ÌÖлúÌå·´Ó¦ÐÔµÄÑо¿¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1. ¼×»ùÜлùÑÇÏõ°·(methyl-benzyl-nitrosamine,MBNA)ÓÕ·¢Ê³¹Ü°© È¡ÌåÖØ100g£¨Ô¼1ÔÂÁ䣩ÒÔÉÏWistar´óÊó £¬ÈÎÆäÒûÓú¬MBNAÒûË® £¬²¢½«1% MBNAÈÜÒº¼ÓÔÚÉÙÁ¿µÄ·Ûĩ״ËÇÁÏÖÐ £¬½Á°èÔȳÆ £¬Óɶ¯Îï×ÔÓÉÉãʳ £¬¸øÒ©Á¿ÎªÌìÌì0.75~1.5mg/kg, 80~100Ìì¿ÉÓÕ·¢Ê³¹Ü°©¡£

2. ¶þÌþ»ÆÕÁËØ(dihydrosafrole)ÓÕ·¢´óÊóʳ¹Ü°©Ä£×Ó ÔÚ´óÊóËÇÁÏÖмÓÈë΢Á¿2500~10 000ppm(1/2500~1/10 000)»ÆÕÁËØÎ¹Ñø´óÊó £¬ÓÕ·¢ÂÊ´ï20%~70%¡£

3. ÓÃ0.2£¥»ò0.005%MBNAË®ÈÜÒº £¬¸ø¶¯Îï¾­¿Ú¹àι £¬ÌìÌìÒ»´Î £¬´óÊó¹à×¢¼ÁÁ¿Îª1mg/kgÌåÖØ £¬ÖÁµÚ27Ìì·ºÆðʳ¹ÜÈéÍ·×´Áö £¬154d·ºÆðʳ¹Ü°© £¬11¸öÔºóʳ¹Ü°©µÄ±¬·¢ÂÊΪ53%¡£

¡¾Ä£×ÓÌØµã¡¿£º

MBNAÓÕ·¢80~100Ìì¿É¼ûʳ¹ÜÁÛ״ϸ°û°©µÄ×éÖ¯ÏñºÍÈËÀàµÄʳ¹ÜÁÛ°©ÏàËÆ £¬µ«ºÜÉÙ±¬·¢×ªÒÆ £¬¸øÒ©Ê±¼äÓú³¤ £¬°©µÄ±¬·¢ÂÊÓú¸ß £¬Ò»Ñùƽ³£¿É´ï80%~100% £¬Í¬Ê±MBNAÖ°©ÐÔ½ÏÇ¿ £¬´ó¼ÁÁ¿1´Î¸øÒ© £¬¼´¿ÉÖ°©¡£ÔÚÄ£×ÓÖÆ±¸Àú³ÌÖÐÒª×¢ÖØ»¯Ñ§ÓÕµ¼¼ÁµÄÖÖÀàºÍ¶¯ÎïÆ·ÏµÑ¡Ôñ £¬Ñо¿·¢Ã÷ÏÖÔÚÓ¦ÓÃ×î¶àµÄÊÇ´óÊó £¬ÆäÖÐÓÖÒÔF344ºÍSprague Dawley´óÊóΪÖ÷¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

ÑÇÏõ°·À໯ºÏÎïÊÇÒ»Ààǿְ©Îï £¬ÄÜÒýÆð¶àÔàÆ÷µÄÖ×Áö £¬ÆäÖÐijЩÖÖÀàµÄÑÇÏõ°·ÔÚ¶¯ÎïÌØÊâÊÇ´óÊóÌåÄÚÊǽÏÇ¿µÄʳ¹Ü°©ÓÕµ¼¼Á £¬ÕâЩ»¯ºÏÎïÖжԴóÊóʳ¹Ü×îÇ¿µÄÖ°©ÎïMBNA¹éÌØÊâµÄʳ¹ÜÇ׺ÍÐÔ £¬ËüÓÕµ¼µÄ°©±ä½öÏÞÓÚʳ¹Ü¡£MBNAÓÕµ¼µÄʳ¹Ü°©Ä£×ÓÖ÷ÒªÓÃÓÚÑо¿×éÖ¯²¡ÀíÑ§ÌØÕ÷ÒÔ¼°¾ÙÐа©±ä»úÖÆ¼°»¯Ñ§Ô¤·À·½ÃæµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.ÎâÁÖ £¬³ÂÁÖÐË £¬³ÂÉ÷ÈÊ£®Ê³¹Ü°©¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®¹ú¼ÊÄ¥Á·Ò½Ñ§ÔÓÖ¾ £¬2007,28 (5):433-435

2.Maliakal PP, Covil.le PF, Wanwimolruk S. Decreased hepatic drug metabolising enzyme activity in rats with nitrosamineinduced tumours. Drug Metabol Drug Interact, 2002, 19 (1):13-27

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > ʳ¹Ü°©¶¯ÎïÄ£×Ó
ʳ¹Ü°©¶¯ÎïÄ£×Ó

ǰÑÔ

ʳ¹Ü°©(esophageal carcinoma)ÊÇÓÉʳ¹ÜÁÛ×´ÉÏÆ¤»òÏÙÉÏÆ¤µÄÒì³£ÔöÉúËùÐγɵĶñÐÔ²¡±ä £¬ÆäÉú³¤Ò»Ñùƽ³£¾­ÓÉÉÏÆ¤²»µä·¶ÔöÉú¡¢Ô­Î»°©¡¢½þÈ󰩵Ƚ׶Ρ£Ê³¹ÜÁÛ×´ÉÏÆ¤²»µä·¶ÔöÉúÊÇʳ¹Ü°©µÄÖ÷Òª°©Ç°²¡±ä £¬Óɲ»µä·¶ÔöÉúµ½°©±äÒ»Ñùƽ³£ÐèÒª¼¸ÄêÉõÖÁÊ®¼¸Äê¡£ÕýÓÉÓÚÔÆÔÆ £¬Ò»Ð©Ê³¹Ü°©¿ÉÒÔÔçÆÚ·¢Ã÷²¢¿ÉÍêÈ«ÖÎÓú¡£¹ØÓÚÍÌÑʲ»³©»òÓÐÒìÎï¸ÐµÄ»¼ÕßÓ¦¾¡Ôç¾ÙÐÐθ¾µ¼ì²éÒԱ㷢Ã÷ÔçÆÚʳ¹Ü°©»ò°©Ç°²¡±ä¡£³£Óö¯ÎïÄ£×ÓΪÓÕ·¢ÐÔʳ¹Ü°©¶¯ÎïÄ£×Ó¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÑÇÏõ°·ÔÚÌåÄÚ¾­ÓÉ´úл £¬±¬·¢ÖØÌ¼ÉÕ £¬Ê¹ºËËá»òÆäËû·Ö×Ó±¬·¢ÉÕ»¯¶øÖ°© £¬²î³Ø³ÆÑÇÏõ°·¿Ú·þ»ò賦Íâ¸øÒ© £¬¾ùÄÜÓÕ·¢´óÊóʳ¹Ü°© £¬¿ÉÓÃÓÚʳ¹Ü°©µÄ×éÖ¯±¬·¢ÆøÖÆ¡¢¿¹Ê³¹Ü°©Ò©ÎïµÄɸѡºÍʳ¹Ü°©±¬·¢Àú³ÌÖлúÌå·´Ó¦ÐÔµÄÑо¿¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1. ¼×»ùÜлùÑÇÏõ°·(methyl-benzyl-nitrosamine,MBNA)ÓÕ·¢Ê³¹Ü°© È¡ÌåÖØ100g£¨Ô¼1ÔÂÁ䣩ÒÔÉÏWistar´óÊó £¬ÈÎÆäÒûÓú¬MBNAÒûË® £¬²¢½«1% MBNAÈÜÒº¼ÓÔÚÉÙÁ¿µÄ·Ûĩ״ËÇÁÏÖÐ £¬½Á°èÔȳÆ £¬Óɶ¯Îï×ÔÓÉÉãʳ £¬¸øÒ©Á¿ÎªÌìÌì0.75~1.5mg/kg, 80~100Ìì¿ÉÓÕ·¢Ê³¹Ü°©¡£

2. ¶þÌþ»ÆÕÁËØ(dihydrosafrole)ÓÕ·¢´óÊóʳ¹Ü°©Ä£×Ó ÔÚ´óÊóËÇÁÏÖмÓÈë΢Á¿2500~10 000ppm(1/2500~1/10 000)»ÆÕÁËØÎ¹Ñø´óÊó £¬ÓÕ·¢ÂÊ´ï20%~70%¡£

3. ÓÃ0.2£¥»ò0.005%MBNAË®ÈÜÒº £¬¸ø¶¯Îï¾­¿Ú¹àι £¬ÌìÌìÒ»´Î £¬´óÊó¹à×¢¼ÁÁ¿Îª1mg/kgÌåÖØ £¬ÖÁµÚ27Ìì·ºÆðʳ¹ÜÈéÍ·×´Áö £¬154d·ºÆðʳ¹Ü°© £¬11¸öÔºóʳ¹Ü°©µÄ±¬·¢ÂÊΪ53%¡£

¡¾Ä£×ÓÌØµã¡¿£º

MBNAÓÕ·¢80~100Ìì¿É¼ûʳ¹ÜÁÛ״ϸ°û°©µÄ×éÖ¯ÏñºÍÈËÀàµÄʳ¹ÜÁÛ°©ÏàËÆ £¬µ«ºÜÉÙ±¬·¢×ªÒÆ £¬¸øÒ©Ê±¼äÓú³¤ £¬°©µÄ±¬·¢ÂÊÓú¸ß £¬Ò»Ñùƽ³£¿É´ï80%~100% £¬Í¬Ê±MBNAÖ°©ÐÔ½ÏÇ¿ £¬´ó¼ÁÁ¿1´Î¸øÒ© £¬¼´¿ÉÖ°©¡£ÔÚÄ£×ÓÖÆ±¸Àú³ÌÖÐÒª×¢ÖØ»¯Ñ§ÓÕµ¼¼ÁµÄÖÖÀàºÍ¶¯ÎïÆ·ÏµÑ¡Ôñ £¬Ñо¿·¢Ã÷ÏÖÔÚÓ¦ÓÃ×î¶àµÄÊÇ´óÊó £¬ÆäÖÐÓÖÒÔF344ºÍSprague Dawley´óÊóΪÖ÷¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

ÑÇÏõ°·À໯ºÏÎïÊÇÒ»Ààǿְ©Îï £¬ÄÜÒýÆð¶àÔàÆ÷µÄÖ×Áö £¬ÆäÖÐijЩÖÖÀàµÄÑÇÏõ°·ÔÚ¶¯ÎïÌØÊâÊÇ´óÊóÌåÄÚÊǽÏÇ¿µÄʳ¹Ü°©ÓÕµ¼¼Á £¬ÕâЩ»¯ºÏÎïÖжԴóÊóʳ¹Ü×îÇ¿µÄÖ°©ÎïMBNA¹éÌØÊâµÄʳ¹ÜÇ׺ÍÐÔ £¬ËüÓÕµ¼µÄ°©±ä½öÏÞÓÚʳ¹Ü¡£MBNAÓÕµ¼µÄʳ¹Ü°©Ä£×ÓÖ÷ÒªÓÃÓÚÑо¿×éÖ¯²¡ÀíÑ§ÌØÕ÷ÒÔ¼°¾ÙÐа©±ä»úÖÆ¼°»¯Ñ§Ô¤·À·½ÃæµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.ÎâÁÖ £¬³ÂÁÖÐË £¬³ÂÉ÷ÈÊ£®Ê³¹Ü°©¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®¹ú¼ÊÄ¥Á·Ò½Ñ§ÔÓÖ¾ £¬2007,28 (5):433-435

2.Maliakal PP, Covil.le PF, Wanwimolruk S. Decreased hepatic drug metabolising enzyme activity in rats with nitrosamineinduced tumours. Drug Metabol Drug Interact, 2002, 19 (1):13-27

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿